When Earlier Is Better But Still Not Cost-Effective ― Reframing the Value of Tafamidis in Transthyretin Amyloid Cardiomyopathy ―

Abstract

No public abstract is available from the verified source records.

Authors

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

europepmc

Confidence 96%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

No local reference links have been materialized yet.

No local citing links have been materialized yet.

10.1253/circj.cj-24-0472

10.1253/circj.cj-24-0479

10.1253/circj.cj-23-0948

10.1253/circj.cj-24-0733

10.1253/circj.cj-24-0666

10.1253/circj.cj-26-0576

10.1161/circulationaha.119.045093

10.1056/nejmoa1805689

10.1002/ejhf.3696

10.1186/1471-2288-12-9

10.1253/circj.cj-24-0402

10.1093/eurheartj/ehx589